Irurzun-Lopez Maite, Erondu Ngozi A, Djibo Ali, Griffiths Ulla, Stuart James M, Fernandez Katya, Ronveaux Olivier, Le Gargasson Jean-Bernard, Gessner Bradford D, Colombini Anaïs
Agence de Médecine Préventive, Bât. JB Say, 4e étage, aile A, 13 chemin du Levant, 01210 Ferney-Voltaire, France(1).
London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, United Kingdom(2).
Vaccine. 2016 Feb 17;34(8):1133-8. doi: 10.1016/j.vaccine.2015.10.045. Epub 2015 Oct 23.
The introduction of serogroup A meningococcal conjugate vaccine in the African meningitis belt required strengthened surveillance to assess long-term vaccine impact. The costs of implementing this strengthening had not been assessed.
The ingredients approach was used to retrospectively determine bacterial meningitis surveillance costs in Chad and Niger in 2012. Resource use and unit cost data were collected through interviews with staff at health facilities, laboratories, government offices and international partners, and by reviewing financial reports. Sample costs were extrapolated to national level and costs of upgrading to desired standards were estimated.
Case-based surveillance had been implemented in all 12 surveyed hospitals and 29 of 33 surveyed clinics in Niger, compared to six out of 21 clinics surveyed in Chad. Lumbar punctures were performed in 100% of hospitals and clinics in Niger, compared to 52% of the clinics in Chad. The total costs of meningitis surveillance were US$ 1,951,562 in Niger and US$ 338,056 in Chad, with costs per capita of US$ 0.12 and US$ 0.03, respectively. Laboratory investigation was the largest cost component per surveillance functions, comprising 51% of the total costs in Niger and 40% in Chad. Personnel resources comprised the biggest expense type: 37% of total costs in Niger and 26% in Chad. The estimated annual, incremental costs of upgrading current systems to desired standards were US$ 183,299 in Niger and US$ 605,912 in Chad, which are 9% and 143% of present costs, respectively.
Niger's more robust meningitis surveillance system costs four times more per capita than the system in Chad. Since Chad spends less per capita, fewer activities are performed, which weakens detection and analysis of cases. Countries in the meningitis belt are diverse, and can use these results to assess local costs for adapting surveillance systems to monitor vaccine impact.
在非洲脑膜炎带引入A群脑膜炎球菌结合疫苗需要加强监测,以评估疫苗的长期影响。实施这种强化监测的成本尚未得到评估。
采用成分法回顾性确定2012年乍得和尼日尔细菌性脑膜炎监测的成本。通过与卫生设施、实验室、政府办公室和国际伙伴的工作人员进行访谈,并审查财务报告,收集资源使用和单位成本数据。将样本成本外推至国家层面,并估算升级到期望标准的成本。
在尼日尔,所有12家接受调查的医院和33家接受调查的诊所中的29家实施了基于病例的监测,而在乍得,21家接受调查的诊所中只有6家实施了该监测。尼日尔100%的医院和诊所进行了腰椎穿刺,而乍得只有52%的诊所进行了腰椎穿刺。脑膜炎监测的总成本在尼日尔为1,951,562美元,在乍得为338,056美元,人均成本分别为0.12美元和0.03美元。实验室调查是每个监测功能中最大的成本组成部分,在尼日尔占总成本的51%,在乍得占40%。人力资源是最大的费用类型:在尼日尔占总成本的37%,在乍得占26%。将当前系统升级到期望标准的估计年度增量成本在尼日尔为183,299美元,在乍得为605,912美元分别占当前成本的9%和143%。
尼日尔更强大的脑膜炎监测系统人均成本是乍得系统的四倍。由于乍得人均支出较少,开展的活动也较少,这削弱了对病例的检测和分析。脑膜炎带的国家各不相同,可利用这些结果评估当地调整监测系统以监测疫苗影响的成本。